Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide

Abstract

Aims

Low prevalence of detectable cardiac troponin in healthy people and low-risk patients previously curtailed its use. With a new high-sensitive cardiac troponin assay (hs-cTnT), concentrations below conventional detection may have prognostic value, notably in combination with N-terminal pro-B-type natriuretic peptide (NT-pro-BNP).

Methods and results

Biomarker concentrations were determined from serum obtained at enrolment in the CLARICOR trial involving 4197 patients with stable coronary artery disease (CAD) followed for 2.6 years. Serum hs-cTnT was detectable (above 3 ng/l) in 78% and above the conventional 99th percentile (13.5 ng/l) in 23%. Across all levels of hs-cTnT there was a graded increase in the risk of cardiovascular death after adjustment for known prognostic indicators: hazard ratio (HR) per unit increase in the natural logarithm of the hs-cTnT level, 1.49; 95% confidence interval (CI), 1.23–1.81; similarly for all-cause mortality (HR 1.48, 95% CI 1.29–1.70) and myocardial infarction (HR 1.37, 95% CI 1.13–1.67). Increasing values of hs-cTnT were associated with increased mortality across all values of NT-pro-BNP, but this was particularly prominent when NT-pro-BNP >400 ng/l.

Conclusions

In patients with stable CAD, any detectable hs-cTnT level is significantly associated with all-cause mortality, cardiovascular death, and myocardial infarction after adjustment for traditional risk factors and NT-pro-BNP. Excess mortality is particularly pronounced in patients with NT-pro-BNP >400 ng/l.

Keywords

Cardiovascular death high-sensitivity troponin T assay NT-pro-BNP risk prediction stable coronary artery disease

Get full access to this article

View all access options for this article.

References

Hickman

Potter

Aroney

. Cardiac troponin may be released by ischemia alone, without necrosis. Clin Chim Acta 2010; 411: 318–323.

Antman

Tanasijevic

Thompson

. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342–1349.

Hamm

Ravkilde

Gerhardt

. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327: 146–150.

Lindahl

Toss

Siegbahn

. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343: 1139–1147.

Ohman

Armstrong

Christenson

. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996; 335: 1333–1341.

deFilippi

Wasserman

Rosanio

. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003; 290: 353–359.

Eggers

Lind

Ahlstrom

. Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur Heart J 2008; 29: 2252–2258.

Sato

Yamada

Taniguchi

. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103: 369–374.

Wallace

Abdullah

Drazner

. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006; 113: 1958–1965.

10.

Zethelius

Johnston

Venge

. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 2006; 113: 1071–1078.

11.

de Lemos

Drazner

Omland

. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503–2512.

12.

Keller

Zeller

Peetz

. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009; 361: 868–877.

13.

Lankeit

Friesen

Aschoff

. Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J 2010; 31: 1836–1844.

14.

Latini

Masson

Anand

. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007; 116: 1242–1249.

15.

Omland

de Lemos

Sabatine

. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009; 361: 2538–2547.

16.

Reichlin

Hochholzer

Bassetti

. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361: 858–867.

17.

Wiese

Breyer

Dragu

. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 2000; 102: 3074–3079.

18.

Bursi

Weston

Redfield

. Systolic and diastolic heart failure in the community. JAMA 2006; 296: 2209–2216.

19.

Cowie

Struthers

Wood

. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349–1353.

20.

Davis

Espiner

Richards

. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343: 440–444.

21.

Bibbins-Domingo

Ansari

Schiller

. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 2003; 108: 2987–2992.

22.

Goetze

Christoffersen

Perko

. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003; 17: 1105–1107.

23.

Goetze

Gore

Moller

. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004; 18: 1928–1930.

24.

Hama

Itoh

Shirakami

. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995; 92: 1558–1564.

25.

James

Lindback

Tilly

. Troponin‐T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol 2006; 48: 1146–1154.

26.

Daniels

Laughlin

Clopton

. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 2008; 52: 450–459.

27.

Kaptoge

Lowe

. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132–140.

28.

Sinning

Bickel

Messow

. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Eur Heart J 2006; 27: 2962–2968.

29.

Gupta

Leatham

Carrington

. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404–407.

30.

Jespersen

Als-Nielsen

Damgaard

. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006; 332: 22–27.

31.

Kjoller

Hilden

Winkel

. Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease. J Clin Epidemiol 2012; 65: 444–453.

32.

Gluud

Als-Nielsen

Damgaard

. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology 2008; 111: 280–287.

33.

Giannitsis

Becker

Kurz

. High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem 2010; 56: 642–650.

34.

Dickstein

Cohen-Solal

Filippatos

. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388–2442.

35.

Pencina

D’Agostino

Sr D’Agostino

Jr . Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157–172.

36.

Ndrepepa

Braun

Schulz

. Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina. Eur J Clin Invest 2011; 41: 1054–1062.

37.

Bibbins-Domingo

Gupta

. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 2007; 297: 169–176.